Myocardial Infarction is another name used in place of heart attack, it is a major cause of death globally. The development of new therapies and treatment is intensified globally, as medical institutions and clinic are strive to improve the outcomes for patient while minimizing its long-term impact on the functioning of heart. This blog will provide an overview on the latest treatment and therapies that are transforming the Myocardial Infarction landscape. To know more about the emerging Myocardial Infarction market kindly visit Coherent market insights recent report.
-
New Drug Therapies for Myocardinal Infarction
The Myocardial Infarction treatment is revolutionizing by the development of new therapies that are designed to enhance the patient recovery and to prevent these further cardiac events. The likelihood of the blood clots can be reduced by the use of antiplatelet agents including ticagrelor and prasugrel and aspirin. However, the anticoagulants that are widely used to manage the clot formation in acute Myocardial Infarction is heparin and newer oral agents such as apixaban.
In Addition, as thrombolytic drugs continue to evolve, the agents such as tenecteplase will offer fast and effective options for the dissolution of clot in STEMI patients. These medication will aid in restoring blood flow to the heart by reducing the damage caused by the infarction and improve the survival rate.
Innovative treatment in the field of drug development are focusing on these regenerative medicines and therapies that aims to promote the cardiac tissue regeneration. Stem cell therapies including transplantation of mesenchymal stem cells are researched for its ability to repair damaged tissues in heart. Progress in these treatment will enhance the recovery after myocardial infarction.
